18295214. SELECTIVE MCL-1 BINDING PEPTIDES simplified abstract (Massachusetts Institute of Technology)
Contents
- 1 SELECTIVE MCL-1 BINDING PEPTIDES
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 SELECTIVE MCL-1 BINDING PEPTIDES - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
SELECTIVE MCL-1 BINDING PEPTIDES
Organization Name
Massachusetts Institute of Technology
Inventor(s)
Raheleh Rezaei-araghi of Brookline MA (US)
Amy E. Keating of Arlington MA (US)
SELECTIVE MCL-1 BINDING PEPTIDES - A simplified explanation of the abstract
This abstract first appeared for US patent application 18295214 titled 'SELECTIVE MCL-1 BINDING PEPTIDES
Simplified Explanation
The abstract describes peptides that bind Mcl-1, compositions containing these polypeptides, and methods of using them in cancer treatment by administering them to a subject.
- Peptides that bind Mcl-1 have been identified.
- Compositions containing these polypeptides are provided.
- Methods of using these peptides in cancer treatment involve administering them to a subject.
Potential Applications
The technology can be applied in the development of new cancer treatments targeting Mcl-1.
Problems Solved
This technology addresses the need for more effective cancer treatments by targeting Mcl-1, a protein involved in cancer cell survival.
Benefits
The use of these peptides can potentially lead to improved cancer treatment outcomes by targeting Mcl-1.
Potential Commercial Applications
The technology has potential commercial applications in the development of novel cancer therapies targeting Mcl-1.
Possible Prior Art
Prior art may include research on Mcl-1 inhibitors or other peptides targeting Mcl-1 in cancer treatment.
Unanswered Questions
What specific types of cancer can be targeted using these peptides?
The abstract does not specify which types of cancer can be treated using the peptides that bind Mcl-1.
Are there any potential side effects associated with administering these peptides to cancer patients?
The abstract does not mention any potential side effects that may be associated with using these peptides in cancer treatment.
Original Abstract Submitted
Provided herein are peptides that bind Mcl-1. Also provided are compositions containing these polypeptides and methods of using such peptides in the treatment of cancer that include administering to a subject one of the polypeptides.
